Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

2.

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Gainor JF, Shaw AT.

Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. Review.

3.

Emerging Biomarkers in Personalized Therapy of Lung Cancer.

Cagle PT, Raparia K, Portier BP.

Adv Exp Med Biol. 2016;890:25-36. doi: 10.1007/978-3-319-24932-2_2. Review.

PMID:
26703797
4.

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K.

Transl Lung Cancer Res. 2015 Apr;4(2):156-64. doi: 10.3978/j.issn.2218-6751.2014.11.11. Review.

5.

RET fusion gene: translation to personalized lung cancer therapy.

Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K.

Cancer Sci. 2013 Nov;104(11):1396-400. doi: 10.1111/cas.12275. Epub 2013 Oct 1. Review.

6.

New targetable oncogenes in non-small-cell lung cancer.

Oxnard GR, Binder A, Jänne PA.

J Clin Oncol. 2013 Mar 10;31(8):1097-104. doi: 10.1200/JCO.2012.42.9829. Epub 2013 Feb 11. Review.

7.

[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].

Xu L, Zhao R, Dong Z, Zhu T.

Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):663-70. doi: 10.3779/j.issn.1009-3419.2013.12.09. Review. Chinese.

8.

Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks.

Seki Y, Mizukami T, Kohno T.

Biomolecules. 2015 Sep 30;5(4):2464-76. doi: 10.3390/biom5042464. Review.

9.

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.

Fernandez-Cuesta L, Thomas RK.

Clin Cancer Res. 2015 May 1;21(9):1989-94. doi: 10.1158/1078-0432.CCR-14-0854. Epub 2014 Dec 11. Review.

10.

Gene aberrations for precision medicine against lung adenocarcinoma.

Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T.

Cancer Sci. 2016 Jun;107(6):713-20. doi: 10.1111/cas.12941. Epub 2016 May 25. Review.

11.

[New targets and new drugs in thoracic oncology].

Rouviere D, Bousquet E, Pons E, Milia JD, Guibert N, Mazieres J.

Rev Mal Respir. 2015 Oct;32(8):867-76. doi: 10.1016/j.rmr.2015.02.091. Epub 2015 Jun 12. Review. French.

PMID:
26076869
12.

Clinical efficacy and possible applications of genomics in lung cancer.

Alharbi KK.

Asian Pac J Cancer Prev. 2015;16(5):1693-8. Review.

13.

Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

Bos M, Gardizi M, Schildhaus HU, Buettner R, Wolf J.

Transl Lung Cancer Res. 2013 Apr;2(2):112-21. doi: 10.3978/j.issn.2218-6751.2013.03.08. Review.

14.

Molecular biology of lung cancer.

Cooper WA, Lam DC, O'Toole SA, Minna JD.

J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90. doi: 10.3978/j.issn.2072-1439.2013.08.03. Review.

15.

Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis.

Sholl LM.

Semin Diagn Pathol. 2015 Sep;32(5):325-33. doi: 10.1053/j.semdp.2015.02.019. Epub 2015 Feb 4. Review.

PMID:
25753527
16.

Biomarkers in lung adenocarcinoma: a decade of progress.

Sholl LM.

Arch Pathol Lab Med. 2015 Apr;139(4):469-80. doi: 10.5858/arpa.2014-0128-RA. Epub 2014 Sep 25. Review.

PMID:
25255293
17.

Genomics driven-oncology: challenges and perspectives.

Normanno N, Cree IA.

BMC Cancer. 2015 Mar 23;15:141. doi: 10.1186/s12885-015-1147-7. Review.

18.

Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.

Mertens F, Antonescu CR, Mitelman F.

Genes Chromosomes Cancer. 2016 Apr;55(4):291-310. doi: 10.1002/gcc.22335. Epub 2015 Dec 18. Review.

PMID:
26684580
Items per page

Supplemental Content

Write to the Help Desk